Fibroblast Growth Factor 21 and Its Association With Oxidative Stress and Lipid Profile in Type 2 Diabetes Mellitus
Open Access
- 4 September 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Abstract
Introduction Cardiovascular diseases are the leading cause of mortality in diabetic patients. Oxidative stress and mitochondria! dysfunction lead to diabetic cardiomyopathy (DCM) characterized by impaired cardiac structure and function. Hyperglycemia causes oxidative stress, which can lead to microvascular complications, macrovascular complications, and atherosclerosis. Peripheral tissues produce fibroblast growth factor 21 (FGF-21), which has anti-inflammatory properties, increases oxidation of fatty acids, and improves insulin sensitivity. Its increased levels are found in metabolic syndrome and type 2 diabetes mellitus and may also lead to coronary heart disease. Our study sought to measure the serum FGF-21 levels and their associations with lipid profile parameters and oxidative stress in patients with type 2 diabetes mellitus. Methodology One-hundred fifty (150) patients of both genders with type 2 diabetes mellitus were recruited along with 150 controls. Simple random sampling was done. After taking relevant history and physical examination, we drew venous blood samples of each patient and sent them to the institutional laboratory for analysis of fasting blood sugar (FBS) levels, glycated hemoglobin (HbA1C), lipid profile, and FGF-21 serum levels. Oxidative stress parameter malondialdehyde (MDA) was estimated and the total antioxidant status by ferric reducing antioxidant power assay (FRAP) was assessed. Patients were followed up after three months to record the glycemic index, and the values were recorded. We used SPSS Software 25.0 (SPSS, Inc., Chicago, USA) to analyze the data. For consideration of results to be statistically significant, a x value of < 0.05 was selected. Results The levels of serum cholesterol, triglycerides, and low-density lipoprotein (LDL) cholesterol were increased in diabetics compared to controls and were statistically significant (p<0.05). High-density lipoprotein (HDL) cholesterol was lower in diabetic patients as compared to the controls (p<0.05). There was a statistically significant increase in the level of MDA in diabetics compared to controls (p(<)0.005). Serum levels of total antioxidant status (FRAP) were decreased in diabetics in comparison with controls (p(<)0.00.5). Serum FGF-21 level was statistically increased in diabetics compared to controls (p(<)0.005). FGF-21 and MDA are positively correlated and FGF-21 and FRAP are negatively correlated. Serum FGF-21 is positively correlated with total cholesterol, triglycerides, serum LDL cholesterol, and HDL cholesterol. Conclusion Our study concludes that there is a significant correlation between fibroblast growth factor 21, oxidative stress, and abnormal lipid profile in type 2 diabetic patients. FGF-21 could be the target of certain medications used to treat metabolic disorders and obesity.Keywords
This publication has 20 references indexed in Scilit:
- FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in miceClinical Science, 2017
- The descriptive study of anxiety levels among diabetics: insulin users versus non-insulin usersInternational Journal of Research in Medical Sciences, 2017
- Adiponectin modulates oxidative stress-induced mitophagy and protects C2C12 myoblasts against apoptosisScientific Reports, 2017
- Fibroblast growth factor 21 and its novel association with oxidative stressRedox Biology, 2017
- Understanding the Physiology of FGF21Annual Review of Physiology, 2016
- Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan CrosstalkDiabetes & Metabolism Journal, 2016
- FGF21 and Cardiac PhysiopathologyFrontiers in Endocrinology, 2015
- Markers of Oxidative Stress during Diabetes MellitusJournal of Biomarkers, 2013
- The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP AssayAnalytical Biochemistry, 1996
- Lipid peroxides and human diseasesChemistry and Physics of Lipids, 1987